

**News Release**

Contact: Bob Linton  
Dudnyk Public Relations  
+1.267.532.1298 (office)  
+1.215.801.2771 (mobile)

**Fujirebio Diagnostics Honored with Pioneer Award from MARF**

*Company Recognized for Substantial Contributions to Mesothelioma Research  
And the MESOMARK™ Test, the First Blood Test for Mesothelioma*

**MALVERN, Pa. – Nov. 7, 2005** – Fujirebio Diagnostics, Inc. (FDI), a world-leader in *in-vitro* diagnostics, was recently honored with a Pioneer Award from the Mesothelioma Applied Research Foundation (MARF). FDI, one of several companies presented with a Pioneer Award at MARF’s Second International Symposium on Malignant Mesothelioma, received the award for substantial contributions to mesothelioma research and the MESOMARK™ test, the first blood test for mesothelioma.

“Fujirebio Diagnostics is committed to providing highly-effective diagnostic tools to better manage this aggressive form of cancer,” said Monte Wiltse, vice president of sales and marketing for FDI. “We at Fujirebio Diagnostics thank MARF for the Pioneer Award and look forward to a continued, productive partnership as we make strides together in overcoming this challenging disease.”

The Pioneer Award features a reproduction of a painting of a compass on a chart by a mesothelioma patient. Chris Hahn, executive director of MARF, explained that the painting symbolically links the pioneer-like journey of mesothelioma patients and researchers today to early American pioneers who explored uninhabited territory for the benefit of others.

-more-

“With Mesothelioma historically having trouble attracting research dollars from companies, the Pioneer Award is meant to thank and honor companies that have significantly invested in improving outcomes for mesothelioma patients,” Hahn said. “Fujirebio Diagnostics is one of the leading biomarker companies in the world. Its investment in this new field of diagnostics improves treatment and life for mesothelioma patients. We’re extremely grateful to Fujirebio Diagnostics for its investment in mesothelioma research. We know the award and discussions at the symposium were encouraging to mesothelioma patients and their families in attendance.”

The MESOMARK test is a manual enzyme-linked immunosorbent assay (ELISA) that works by identifying biomarkers called soluble mesothelin-related peptides (SMRP). These proteins are released into the bloodstream by malignant mesothelioma cells.

### **About Mesothelioma**

Malignant Pleural Mesothelioma is a highly aggressive form of cancer found in the lining of the chest, the abdominal cavity and around the heart, in which fluid accumulates between the lining of the lungs and chest cavity. Mesothelioma is primarily caused by work-related asbestos exposure and has an average latency period of up to 50 years. It is estimated that more than 100 million people worldwide have been occupationally exposed to asbestos in the past five decades.

### **About MARF**

MARF is a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease. For more information, please visit [www.marf.org](http://www.marf.org).

### **About FDI**

Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in tumor marker assays. FDI specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. In November 1998, Fujirebio, Inc. of Tokyo, Japan, acquired the company, formerly known as Centocor Diagnostics. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit [www.fdi.com](http://www.fdi.com).

# # #

**Forward-Looking Statement**

Any statements in this press release about future expectations, plans or prospects for the Company, including the Company's expectations and its plans to complete the FDA approval process for MESOMARK constitute forward-looking statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. FDI undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect FDI's business.